000			03429nam a22004695i 4500
001			978-0-387-69259-3
003			DE-He213
005			20140220084454.0
007			cr nn 008mamaa
008			100715s2010 xxu| s |||| 0|eng d
020			_a9780387692593 _9978-0-387-69259-3
024	7		_a10.1007/978-0-387-69259-3 _2doi
050		4	_aRC254-282
072		7	_aMJCL _2bicssc
072		7	_aMED062000 _2bisacsh
082	0	4	_a616.994 _223
100	1		_aNagarajan, Lalitha. _eeditor.
245	1	0	_aAcute Myelogenous Leukemia _h[electronic resource] : _bGenetics, Biology and Therapy / _cedited by Lalitha Nagarajan.
250			_a1.
264		1	_aNew York, NY : _bSpringer New York, _c2010.
300			_aIX, 280 p. _bonline resource.
336			_atext _btxt _2rdacontent
337			_acomputer _bc _2rdamedia
338			_aonline resource _bcr _2rdacarrier
347			_atext file _bPDF _2rda
490	1		_aCancer Treatment and Research, _x0927-3042 ; _v145
505	0		_aThe Leukemia Stem Cell -- Epigenetic Mechanisms in AML – A Target for Therapy -- Chromosomal Translocations in AML: Detection and Prognostic Significance -- Chromosomal Deletions in AML -- Genes Predictive of Outcome and Novel Molecular Classification Schemes in Adult Acute Myeloid Leukemia -- Receptor Tyrosine Kinase Alterations in AML – Biology and Therapy -- Lineage-Specific Transcription Factor Aberrations in AML -- Proleukemic RUNX1 and CBF? Mutations in the Pathogenesis of Acute Leukemia -- Acute Myeloid Leukemia with Mutated Nucleophosmin (NPM1): Molecular, Pathological, and Clinical Features -- MicroRNAs: New Players in AML Pathogenesis -- Murine Models of Human Acute Myeloid Leukemia -- Apoptosis in Leukemias: Regulation and Therapeutic Targeting -- Acute Promyelocytic Leukemia: A Paradigm for Differentiation Therapy -- Immunotherapy of AML -- Therapy of Acute Myelogenous Leukemia in Adults.
520			_aAcute myelogenous leukemia (AML), is the most common form of leukemia in adults. AML is a deadly form of malignancy, the prognosis for which has not improved in the last two decades. More importantly, it is a malignancy that is seen in older adults, therefore the number of cases is likely to rise as the population ages. Over the past 15 years, genetic mechanisms underlying AML have begun to unfold. Additional research in this area has helped identify key components and characteristics. Consequently, targeted therapy of AML is receiving much attention. It is the hope of researchers that as with chronic myelogenous leukemia (CML), and the drug, Gleevec, a targeted therapy for AML will be discovered. "The effective treatment of acute myelogenous leukemia remains a great challenge. This text reviews our understanding of the molecular and biologic basis of the disease. Leading investigators address advances in prognostication and therapeutic strategies that have significant promise." Steven T. Rosen, M.D. Series Editor
650		0	_aMedicine.
650		0	_aHematology.
650		0	_aOncology.
650	1	4	_aMedicine & Public Health.
650	2	4	_aOncology.
650	2	4	_aHematology.
710	2		_aSpringerLink (Online service)
773	0		_tSpringer eBooks
776	0	8	_iPrinted edition: _z9780387692579
830		0	_aCancer Treatment and Research, _x0927-3042 ; _v145
856	4	0	_uhttp://dx.doi.org/10.1007/978-0-387-69259-3
912			_aZDB-2-SME
999			_c109769 _d109769